XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Gross Profit	0.05	-	-	-	-	-
Selling, General & Admin	1.53	0.73	0.85	1	0.91	0.81
Research & Development	0.07	0.03	0.03	0.03	0.04	0.04
Operating Expenses	1.61	0.77	0.88	1.03	0.95	0.84
Operating Income	-1.56	-0.77	-0.88	-1.03	-0.95	-0.84
Interest Expense	-0.04	-	-	-	-	-
Interest & Investment Income	0.04	0.04	0.04	0.01	0.03	0.09
Currency Exchange Gain (Loss)	-0.03	-0.03	-0.02	0.01	0.01	0.01
Other Non Operating Income (Expenses)	-0	-0	1.04	0.7	-2.19	0.56
EBT Excluding Unusual Items	-1.59	-0.76	0.18	-0.31	-3.09	-0.19
Gain (Loss) on Sale of Investments	0.53	-1.02	-1.53	0.75	0.14	-0.57
Pretax Income	-1.06	-1.78	-1.35	0.44	-2.95	-0.76
Earnings From Continuing Operations	-1.06	-1.78	-1.35	0.44	-2.95	-0.76
Net Income	-1.06	-1.78	-1.35	0.44	-2.95	-0.76
Net Income to Common	-1.06	-1.78	-1.35	0.44	-2.95	-0.76
Shares Outstanding (Basic)	588	545	545	532	514	514
Shares Outstanding (Diluted)	588	545	545	616	514	514
Shares Change (YoY)	7.97%	-0.00%	-11.48%	19.71%	-	-
EPS (Basic)	-0.00	-0.00	-0.00	0.00	-0.01	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	0.00	-0.01	-0.00
Free Cash Flow	-	-0.71	-0.9	-1.05	-0.85	-0.91
Free Cash Flow Per Share	-	-0.00	-0.00	-0.00	-0.00	-0.00
EBITDA	-	-0.76	-0.88	-1.03	-0.95	-
D&A For EBITDA	-	0	0	0	0	-
EBIT	-1.56	-0.77	-0.88	-1.03	-0.95	-0.84

Updated Dec 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q